ArticleFrontiers in medicine2025
The role of ATG16L1 in Crohn's disease and the structural alteration mechanisms and functional consequences of the rs2241880 variant.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in the management of small bowel Crohn's disease.The Korean journal of internal medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: ATG16L1 (Autophagy Related 16 Like 1) is a key regulatory protein in the autophagy pathway. Although previous studies have established a significant association between the ATG16L1 genotype and Crohn's disease (CD) susceptibility, the specific molecular mechanism of its high-frequency missense variant rs2241880 has yet to be systematically elucidated. Methods: In this study, we first confirmed the important role of ATG16L1 in CD pathogenesis through genome-wide association study analysis and Western blot, as well as qRT-PCR. Subsequently, high-precision structural prediction, protein model-based dynamic simulation, and AI model thermodynamic stability analysis were innovatively integrated. The thermal shift assay (TSA) was employed to validate the structural stability of the mutant, while the pull-down assay was used to examine its binding capacity with WIPI2b. Results: The results show that ATG16L1 plays a significant role in the pathogenesis of CD. The mutation causes the protein's overall conformation to become more compact, significantly increasing the rigidity of key functional regions, and enhancing the structural and thermodynamic stability, which in turn affects the cleavage efficiency of caspase-3 and the function of the WD40 domain. The results of the TSA experiment provided evidence for the computational findings. The pull-down assay confirmed that the binding capacity of the mutant to WIPI2b was significantly impaired. Conclusion: This finding not only provides the first molecular mechanism of the ATG16L1 T300A mutation, offering an important theoretical basis for understanding CD susceptibility differences, but also provides insights for precision medicine interventions and gene editing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.